However, inhibition of EphB4/EphrinB2 forward signaling with sEphB4-MSA resulted in a decrease in U48484 tumor growth (Fig 2A; p = 0.043), suggesting that EphB4/EphrinB2 forward signaling contributes to aRMS progression in vivo. Here, EFNB2 is linked to neoplasm.